Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody

Journal of Immunology

Volumn 192, Issue 8, 2014, Pages 3828-3836

  Russell, Chris B ^a   Rand, Hugh ^a   Bigler, Jeannette ^a   Kerkof, Keith ^a   Timour, Martin ^a   Bautista, Edgar ^b   Krueger, James G ^c   Salinger, David H ^a   Welcher, Andrew A ^b   Martin, David A ^a  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES, MONOCLONAL; CLUSTER ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; KERATINOCYTES; PSORIASIS; RECEPTORS, INTERLEUKIN-17; SKIN; T-LYMPHOCYTES; TRANSCRIPTOME;

EID: 84898658026     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301737     Document Type: Article

References (38)

1. Gudjonsson, J. E., and J. T. Elder. 2007. Psoriasis: epidemiology. Clin. Dermatol. 25: 535-546.
2. Naldi, L. 2004. Epidemiology of psoriasis. Curr. Drug Targets Inflamm. Allergy 3: 121-128.
3. Parisi, R., D. P. Symmons, C. E. Griffiths, D. M. Ashcroft, and Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. 2013. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Invest. Dermatol. 133: 377-385.
4. Schön, M. P., and W. H. Boehncke. 2005. Psoriasis. N. Engl. J. Med. 352: 1899-1912.
5. Lowes, M. A., C. B. Russell, D. A. Martin, J. E. Towne, and J. G. Krueger. 2013. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 34: 174-181.
6. Martin, D. A., J. E. Towne, G. Kricorian, P. Klekotka, J. E. Gudjonsson, J. G. Krueger, and C. B. Russell. 2013. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J. Invest. Dermatol. 133: 17-26.
7. Gaffen, S. L. 2011. Recent advances in the IL-17 cytokine family. Curr. Opin. Immunol. 23: 613-619.
8. Johnston, A., Y. Fritz, S. M. Dawes, D. Diaconu, P. M. Al-Attar, A. M. Guzman, C. S. Chen, W. Fu, J. E. Gudjonsson, T. S. McCormick, and N. L. Ward. 2013. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J. Immunol. 190: 2252-2262.
9. Ramirez-Carrozzi, V., A. Sambandam, E. Luis, Z. Lin, S. Jeet, J. Lesch, J. Hackney, J. Kim, M. Zhou, J. Lai, et al. 2011. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat. Immunol. 12: 1159-1166.
10. Zaba, L. C., M. Suárez-Fariñas, J. Fuentes-Duculan, K. E. Nograles, E. Guttman-Yassky, I. Cardinale, M. A. Lowes, and J. G. Krueger. 2009. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J. Allergy Clin. Immunol. 124: 1022-1030, e1-e395.
11. Capon, F., P. Di Meglio, J. Szaub, N. J. Prescott, C. Dunster, L. Baumber, K. Timms, A. Gutin, V. Abkevic, A. D. Burden, et al. 2007. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122: 201-206.
12. Hueber, W., D. D. Patel, T. Dryja, A. M. Wright, I. Koroleva, G. Bruin, C. Antoni, Z. Draelos, M. H. Gold, P. Durez, et al. 2010. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2: 52ra72.
13. Leonardi, C., R. Matheson, C. Zachariae, G. Cameron, L. Li, E. Edson-Heredia, D. Braun, and S. Banerjee. 2012. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366: 1190-1199.
14. Papp, K. A., C. Leonardi, A. Menter, J. P. Ortonne, J. G. Krueger, G. Kricorian, G. Aras, J. Li, C. B. Russell, E. H. Thompson, and S. Baumgartner. 2012. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366: 1181-1189.
15. Papp, K. A., C. Reid, P. Foley, R. Sinclair, D. H. Salinger, G. Williams, H. Dong, J. G. Krueger, C. B. Russell, and D. A. Martin. 2012. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J. Invest. Dermatol. 132: 2466-2469.
16. Krueger, J. G., S. Fretzin, M. Suárez-Fariñas, P. A. Haslett, K. M. Phipps, G. S. Cameron, J. McColm, A. Katcherian, I. Cueto, T. White, et al. 2012. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J. Allergy Clin. Immunol. 130: 145-154, e9.
17. Endres, C., D. Salinger, M. Gastonguay, E. Thompson, S. Lin, and M. Gibbs. 2012. Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies. Clin. Pharmacol. Drug Dev. 1: 175-229.
18. Bigler, J., H. A. Rand, K. Kerkof, M. Timour, and C. B. Russell. 2013. Crossstudy homogeneity of psoriasis gene expression in skin across a large expression range. PLoS One 8: e52242.
19. Chamian, F., M. A. Lowes, S. L. Lin, E. Lee, T. Kikuchi, P. Gilleaudeau, M. Sullivan-Whalen, I. Cardinale, A. Khatcherian, I. Novitskaya, et al. 2005. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl. Acad. Sci. USA 102: 2075-2080.
20. Wickham, H. 2009. ggplot2: elegant graphics for data analysis. New York: Springer.
21. Bolstad, B. M., F. Collin, K. M. Simpson, R. A. Irizarry, and T. P. Speed. 2004. Experimental design and low-level analysis of microarray data. Int. Rev. Neurobiol. 60: 25-58.
22. Nograles, K. E., L. C. Zaba, E. Guttman-Yassky, J. Fuentes-Duculan, M. Suárez-Fariñas, I. Cardinale, A. Khatcherian, J. Gonzalez, K. C. Pierson, T. R. White, et al. 2008. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159: 1092-1102.
23. Lowes, M. A., T. Kikuchi, J. Fuentes-Duculan, I. Cardinale, L. C. Zaba, A. S. Haider, E. P. Bowman, and J. G. Krueger. 2008. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 128: 1207-1211.
24. Papp, K. A., R. G. Langley, M. Lebwohl, G. G. Krueger, P. Szapary, N. Yeilding, C. Guzzo, M. C. Hsu, Y. Wang, S. Li, et al. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371: 1675-1684.
25. Chiricozzi, A., E. Guttman-Yassky, M. Suárez-Fariñas, K. E. Nograles, S. Tian, I. Cardinale, S. Chimenti, and J. G. Krueger. 2011. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J. Invest. Dermatol. 131: 677-687.
26. Vigne, S., G. Palmer, C. Lamacchia, P. Martin, D. Talabot-Ayer, E. Rodriguez, F. Ronchi, F. Sallusto, H. Dinh, J. E. Sims, and C. Gabay. 2011. IL-36R ligands are potent regulators of dendritic and T cells. Blood 118: 5813-5823.
27. Johnston, A., X. Xing, W. R. Swindell, J. Kochkodan, M. Riblett, R. P. Nair, P. E. Stuart, J. Ding, J. J. Voorhees, J. T. Elder, and J. E. Gudjonsson. 2013. Susceptibility-associated genetic variation at IL12B enhances Th1 polarization in psoriasis. Hum. Mol. Genet. 22: 1807-1815.
28. Collison, L. W., C. J. Workman, T. T. Kuo, K. Boyd, Y. Wang, K. M. Vignali, R. Cross, D. Sehy, R. S. Blumberg, and D. A. Vignali. 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450: 566-569.
29. Johnson-Huang, L. M., M. Suárez-Fariñas, K. C. Pierson, J. Fuentes-Duculan, I. Cueto, T. Lentini, M. Sullivan-Whalen, P. Gilleaudeau, J. G. Krueger, A. S. Haider, and M. A. Lowes. 2012. A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin. J. Invest. Dermatol. 132: 1177-1187.
30. Mitra, A., S. K. Raychaudhuri, and S. P. Raychaudhuri. 2012. Functional role of IL-22 in psoriatic arthritis. Arthritis Res. Ther. 14: R65.
31. Zheng, Y., D. M. Danilenko, P. Valdez, I. Kasman, J. Eastham-Anderson, J. Wu, and W. Ouyang. 2007. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 648-651.
32. Cho, K. A., J. W. Suh, K. H. Lee, J. L. Kang, and S. Y. Woo. 2012. IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1b by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int. Immunol. 24: 147-158.
33. Guilloteau, K., I. Paris, N. Pedretti, K. Boniface, F. Juchaux, V. Huguier, G. Guillet, F. X. Bernard, J. C. Lecron, and F. Morel. 2010. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1a, and TNF-α recapitulates some features of psoriasis. J. Immunol. 184: 5263-5270.
34. Zaba, L. C., I. Cardinale, P. Gilleaudeau, M. Sullivan-Whalen, M. Suárez-Fariñas, J. Fuentes-Duculan, I. Novitskaya, A. Khatcherian, M. J. Bluth, M. A. Lowes, and J. G. Krueger. 2007. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204: 3183-3194.
35. Puel, A., S. Cypowyj, J. Bustamante, J. F. Wright, L. Liu, H. K. Lim, M. Migaud, L. Israel, M. Chrabieh, M. Audry, et al. 2011. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332: 65-68.
36. Nestle, F. O., and M. Gilliet. 2005. Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J. Invest. Dermatol. 125: xiv-xv.
37. Kimball, A. B., K. B. Gordon, R. G. Langley, A. Menter, E. K. Chartash, J. Valdes, and ABT-874 Psoriasis Study Investigators. 2008. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch. Dermatol. 144: 200-207.
38. Papp, K. A., S. Tyring, M. Lahfa, J. Prinz, C. E. Griffiths, A. M. Nakanishi, R. Zitnik, P. C. van de Kerkhof, L. Melvin, and Etanercept Psoriasis Study Group. 2005. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 152: 1304-1312.